SEARCH

SEARCH BY CITATION

References

  • Allford, S.L., Harrison, P., Lawrie, A.S., Liesner, R., MacKie, I.J. & Machin, S.J. (2000) Von Willebrand factor – cleaving protease activity in congenital thrombotic thrombocytopenic purpura. British Journal Haematology, 111, 12151222.
  • Allford, S.L., Hunt, B.J., Rose, P. & Machin, S.J. (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. British Journal of Haematology, 120, 556573.
  • Bandarenko, N. & Brecher, M.E. (1998) United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. Journal of Clinical Apheresis, 13, 133141.
  • Bianchi, V., Robles, R., Alberio, L., Furlan, M. & Lammle, B. (2002) Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood, 100, 710713.
  • Bohm, M., Betz, C., Miesbach, W., Krause, M., Von Auer, C., Geiger, H. & Scharrer, I. (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. British Journal of Haematology, 129, 644652.
  • Coppo, P., Bengoufa, D., Veyradier, A., Wolf, M., Bussel, A., Millot, G.A., Malot, S., Heshmati, F., Mira, J.P., Boulanger, E., Galicier, L., Durey-Dragon, M.A., Fremeaux-Bacchi, V., Ramakers, M., Pruna, A., Bordessoule, D., Gouilleux, V., Scrobohaci, M.L., Vernant, J.P., Moreau, D., Azoulay, E., Schlemmer, B., Guillevin, L. & Lassoued, K. (2004) Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore), 83, 233244.
  • Coppo, P., Wolf, M., Veyradier, A., Bussel, A., Malot, S., Millot, G.A., Daubin, C., Bordessoule, D., Pene, F., Mira, J.P., Heshmati, F., Maury, E., Guidet, B., Boulanger, E., Galicier, L., Parquet, N., Vernant, J.P., Rondeau, E., Azoulay, E. & Schlemmer, B. (2006) Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. British Journal of Haematology, 132, 6674.
  • Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.L., Vanhille, P., Vernant, J.P., Meyer, D. & Veyradier, A. (2006) Prognostic value of anti-ADAMTS13 antibodies features (Ig isotype, titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity. Blood, 109, 28152822.
  • Furlan, M., Robles, R. & Lamie, B. (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 87, 42234234.
  • Furlan, M., Robles, R., Solenthaler, M., Wassmer, M., Sandoz, P. & Lammle, B. (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood, 89, 30973103.
  • Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998a) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. The New England Journal of Medicine, 339, 15781584.
  • Furlan, M., Robles, R., Solenthaler, M. & Lammle, B. (1998b) Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood, 91, 28392846.
  • Galbusera, M., Bresin, E., Noris, M., Gastoldi, S., Belotti, D., Capoferri, C., Daina, E., Perseghin, P., Scheiflinger, F., Fakhouri, F., Grunfeld, J.P., Pogliani, E. & Remuzzi, G. (2005) Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 106, 925928.
  • Gerritsen, H.E., Turecek, P.L., Schwarz, H.P., Lammle, B. & Furlan, M. (1999) Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thrombosis and Haemostasis, 82, 13861389.
  • Klaus, C., Plaimauer, B., Studt, J.D., Dorner, F., Lammle, B., Mannucci, P.M. & Scheiflinger, F. (2004) Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood, 103, 45144519.
  • Lammle, B., Kremer Hovinga, J.A. & Alberio, L. (2005) Thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 3, 16631675.
  • Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, Jr, J.D., Ginsburg, D. & Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488494.
  • McCrae, K.R. & Cines, D.B. (1997) Thrombotic microangiopathy during pregnancy. Seminars in Hematology, 34, 148158.
  • Miller, R.F., Scully, M., Cohen, H., Roedling, S., Starke, R., Edwards, S.G. & Machin, S.J. (2005) Thrombotic thrombocytopaenic purpura in HIV-infected patients. International Journal of STD & AIDS, 16, 538542.
  • Moore, J.C., Hayward, C.P., Warkentin, T.E. & Kelton, J.G. (2001) Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood, 98, 18421846.
  • Moschcowitz, E. (1924) Hyaline thrombosis of the terminal arterioles and capillaries: a hithero undescribed disease. Proceedings of the New York Pathological Society, 24, 2124.
  • Peyvandi, F., Ferrari, S., Lavoretano, S., Canciani, M.T. & Mannucci, P.M. (2004) von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 127, 433439.
  • Rieger, M., Mannucci, P.M., Kremer Hovinga, J.A., Herzog, A., Gerstenbauer, G., Konetschny, C., Zimmermann, K., Scharrer, I., Peyvandi, F., Galbusera, M., Remuzzi, G., Bohm, M., Plaimauer, B., Lammle, B. & Scheiflinger, F. (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 106, 12621267.
  • Rose, M. & Eldor, A. (1987) High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. American Journal of Medicine, 83, 437444.
  • Scheiflinger, F., Knobl, P., Trattner, B., Plaimauer, B., Mohr, G., Dockal, M., Dorner, F. & Rieger, M. (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood, 102, 32413243.
  • Scully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I. & Machin, S.J. (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 136, 451461.
  • Shumak, K.H., Rock, G.A. & Nair, R.C. (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Annals of Internal Medcine, 122, 569572.
  • Starke, R., Machin, S., Scully, M., Purdy, G. & Mackie, I. (2007) The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. British Journal of Haematology, 136, 649655.
  • Terrell, D.R., Williams, L.A., Vesely, S.K., Lammle, B., Hovinga, J.A. & George, J.N. (2005) The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. Journal of Thrombosis and Haemostasis, 3, 14321436.
  • Tsai, H.M. (2000) High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. American Journal of Hematology, 65, 251255.
  • Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. The New England Journal of Medicine, 339, 15851594.
  • Tuncer, H.H., Oster, R.A., Huang, S.T. & Marques, M.B. (2007) Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion, 47, 107114.
  • Vesely, S.K., George, J.N., Lammle, B., Studt, J.D., Alberio, L., El Harake, M.A. & Raskob, G.E. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 102, 6068.
  • Vesely, S.K., Li, X., McMinn, J.R., Terrell, D.R. & George, J.N. (2004) Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 44, 11491158.
  • Veyradier, A., Obert, B., Houllier, A., Meyer, D. & Girma, J.P. (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood, 98, 17651772.
  • Wyllie, B.F., Garg, A.X., Macnab, J., Rock, G.A. & Clark, W.F. (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. British Journal of Haematology, 132, 204209.
  • Yarranton, H., Lawrie, A.S., MacKie, I.J., Pinkoski, L., Corash, L. & Machin, S.J. (2005) Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion, 45, 14531458.